Scaling the production of biotherapeutics is challenging and requires more than just multiplying the ingredients in a recipe. That’s true for gene therapies as well where simply changing the nucleic acid of the payload can have dramatic effects on the product. Form Bio is seeking to address the challenges of making genetic medicines by leveraging AI to accelerate the development of cell and gene therapies. We spoke to Claire Aldridge, chief strategy officer for Form Bio, about the challenges of developing gene therapies, how Form’s AI platform can address that, and how it works grows out of tools that were developed to bring the wooly mammoth back from extinction.